bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note released on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on the company. Barclays reduced their price objective on bluebird bio from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Friday, November 15th. JPMorgan Chase & Co. lowered bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Robert W. Baird reduced their target price on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. Wells Fargo & Company dropped their price objective on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 25th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.03.

bluebird bio Stock Down 2.8 %

Shares of BLUE stock opened at $0.29 on Monday. bluebird bio has a 1 year low of $0.29 and a 1 year high of $5.53. The firm has a market capitalization of $57.28 million, a P/E ratio of -0.16 and a beta of 0.76. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The firm’s fifty day moving average price is $0.47 and its two-hundred day moving average price is $0.77.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. The firm had revenue of $18.57 million during the quarter. On average, equities analysts predict that bluebird bio will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors have recently added to or reduced their stakes in BLUE. Allegheny Financial Group LTD bought a new position in shares of bluebird bio during the second quarter valued at $25,000. Verition Fund Management LLC bought a new position in bluebird bio during the 3rd quarter worth $42,000. Bayesian Capital Management LP bought a new stake in shares of bluebird bio in the 1st quarter valued at about $52,000. SG Americas Securities LLC increased its stake in shares of bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 74,185 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 29,113 shares during the last quarter. 87.43% of the stock is owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.